Copyright
©The Author(s) 2021.
World J Clin Cases. Nov 26, 2021; 9(33): 10064-10074
Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10064
Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10064
Anti-diabetic drugs | Effect on sarcopenia | Good option or poor option |
Biguanides | Positive[31,33-36,38-40]/negative[41-44] | Unclear |
Insulin secretagogues | Negative[46-48] | Poor |
-Glucosidase inhibitors | No data | No data |
Thiazolidinediones | Positive[35,53-56] | Careful use |
Dipeptidyl peptidase IV inhibitors | Positive[57-60]/neutral[62] | Good |
Glucagon-like peptide-1 receptor agonists | Positive[63,70,71]/negative[62] | Unclear |
Sodium-glucose cotransporter-2 inhibitor | Positive[72,73]/unclear[6,74] | Unclear |
Insulin | Positive/unclear[75] | Unclear |
- Citation: Ma XY, Chen FQ. Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World J Clin Cases 2021; 9(33): 10064-10074
- URL: https://www.wjgnet.com/2307-8960/full/v9/i33/10064.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i33.10064